# Cannabis Drug Interaction Check (Free) – Green Bridge Society > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-drug-interaction-check-free-green-bridge-society/ > **Published:** 2026-06-02T23:47:41-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:53:41-04:00 > **Clinical Summary:** Cannabis drug interactions screening tool and clinical guide for anticoagulants, antidepressants, sedatives, and more. --- ✦ New CED Clinical Relevance #81 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. SafetyDrug Interactions[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)ResearchCBDTHCDosing I apologize – I need to correct myself as “Drug Interactions” is not in the allowed list. Safety Why This Matters Clinicians need to systematically screen for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and potential drug interactions since cannabis inhibits cytochrome P450 enzymes, affecting metabolism of anticoagulants, antidepressants, and sedatives with significant clinical consequences. Patients using cannabis alongside these medications may experience altered drug efficacy or increased adverse effects, making accessible interaction-checking tools essential for safe prescribing and dosing decisions. This resource enables clinicians to quickly identify interaction risks during patient encounters, supporting informed counseling and medication adjustments to prevent treatment failures or toxicity. Clinical Summary Cannabis has clinically significant interactions with multiple commonly prescribed medication classes, including anticoagulants, antidepressants, and sedatives, which can alter drug metabolism and efficacy. The Green Bridge Society provides a free [drug interaction](https://cedclinic.com/glp-1-addiction-risk-reduction-benefits/) checking tool designed to help patients and clinicians identify potential interactions between cannabis and concomitant medications. Given that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) among patients taking prescription medications is increasingly common, awareness of these interactions is essential for safe prescribing and [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/). The cytochrome P450 enzyme inhibition caused by cannabinoids can elevate plasma concentrations of drugs metabolized through this pathway, potentially increasing adverse effects or therapeutic failure depending on the medication. Clinicians should routinely screen for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) when evaluating medication efficacy or unexplained [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/), and consider using readily available interaction tools to guide [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/) and dosing adjustments. Integrating cannabis interaction screening into standard medication review processes will help minimize preventable adverse events and optimize therapeutic outcomes in patients using both cannabis and conventional medications. Dr. Caplan’s Take “When a patient tells me they’re using cannabis, the first thing I do is run through their medication list for CYP3A4 and CYP2C19 interactions, because we’re not talking about theoretical risk here—I’ve seen real cases where cannabis elevated warfarin levels dangerously or potentiated benzodiazepines beyond what the patient expected. Having a reliable interaction checker available to patients means they’re more likely to be honest with me about their use, which is where good medicine actually starts.” Clinical Perspective As cannabis use becomes increasingly common among patients taking prescription medications, clinicians should be aware that cannabinoids can inhibit cytochrome P450 enzymes, potentially elevating levels of drugs metabolized through these pathways, including warfarin, certain antidepressants, and benzodiazepines. While free online interaction checkers like those offered by the Green Bridge Society provide accessible preliminary screening, these tools have notable limitations: they may not capture all relevant interactions, vary in scientific rigor, and cannot replace individualized clinical assessment that considers a patient’s complete medication profile, dosing regimens, and specific cannabinoid composition. The clinical challenge is compounded by the lack of standardized dosing and variable cannabinoid concentrations across cannabis products, making it difficult to predict interaction magnitude in practice. Practically, clinicians should routinely ask patients about cannabis use during medication reconciliation, maintain a lower threshold for checking established [drug interaction](https://cedclinic.com/glp-1-addiction-risk-reduction-benefits/) databases 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Drug%20Interaction%20Check%20%28Free%29%20-%20Green%20Bridge%20Society%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57531)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57531)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Drug%20Interaction%20Check%20%28Free%29%20-%20Green%20Bridge%20Society%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57531)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.greenbridgesociety.com/cannabis-drug-interactions](https://www.greenbridgesociety.com/cannabis-drug-interactions) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).